Alnylam: Q3 Earnings Snapshot

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Alnylam Pharmaceuticals Inc. (ALNY) on Thursday reported a third-quarter loss of $111.6 million, after reporting a profit in the same period a year earlier.

The Cambridge, Massachusetts-based company said it had a loss of 87 cents per share. Losses, adjusted for stock option expense and non-recurring costs, were 50 cents per share.

The results matched Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was also for a loss of 50 cents per share.

The RNA interference drug developer posted revenue of $500.9 million in the period, missing Street forecasts. Eleven analysts surveyed by Zacks expected $529.3 million.

Alnylam shares have risen 47% since the beginning of the year. The stock has increased 86% in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ALNY at https://www.zacks.com/ap/ALNY

Copyright © 2024 The Associated Press. All rights reserved. This material may not be published, broadcast, written or redistributed.

Federal News Network Logo
Log in to your WTOP account for notifications and alerts customized for you.

Sign up